Avenue therapeutics completes the acquisition of baergic bio and its selective gaba-a Α2/3 receptor positive allosteric modulator for the treatment of central nervous system disorders

New york, nov. 08, 2022 (globe newswire) -- avenue therapeutics, inc. (nasdaq: atxi) (“avenue” or the “company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system (“cns”) diseases, today announced the closing of the acquisition of baergic bio, inc. (“baergic bio”) pursuant to the previously disclosed share contribution agreement with its parent company, fortress biotech, inc.
ATXI Ratings Summary
ATXI Quant Ranking